In brief
Amid rising global concerns about antibiotic resistance, India is making strides with locally-developed medications aimed at addressing this urgent health issue, potentially transforming treatment paradigms.
India is facing a medical crisis as antibiotic-resistant bacteria—often referred to as "superbugs"—continue to thrive. According to The Lancet, these infections claimed 1.14 million lives worldwide in 2021 alone, with India reporting around 300,000 deaths from such infections in 2019. Alarmingly, nearly 60,000 newborns die every year due to these scourges. In response, Indian pharmaceutical companies are forging ahead with groundbreaking drugs designed to combat these formidable pathogens. Enmetazobactam, for instance, is a pioneering antimicrobial developed by Chennai’s Orchid Pharma, which recently gained FDA approval. This drug uniquely binds to the bacteria's defensive enzymes, allowing existing antibiotics to work effectively again, thereby preserving critical last-resort treatments. Furthermore, clinical trials across 19 countries have validated its effectiveness, particularly in critical care settings.Mumbai's Wockhardt is also in the spotlight with its antibiotic Zaynich, which has shown promising results and is in Phase-3 trials. Early compassionate use in critically ill patients has yielded survival for all 30 participants who were unresponsive to existing antibiotics. Additionally, Wockhardt's Nafithromycin, an oral treatment for pneumonia, boasts a remarkable 97% success rate in trials, highlighting its potential to address rising resistance rates previously reported at 60%.Collaborations are also emerging, such as the Bengaluru-based Bugworks Research working with the Global Antibiotic Research and Development Partnership (GARDP) to innovate a new class of antibiotics. However, they face an uphill challenge as limited investment in antibiotics compared to other drug categories means research and development funding remains inadequate.With resistance rates peaking, particularly with pathogens like E.coli and Klebsiella pneumoniae, experts stress the importance of stringent antibiotic use practices. Currently, broad-spectrum antibiotics are frequently prescribed, exacerbating resistance. Medical professionals advocate for narrow-spectrum alternatives alongside improved antibiotic prescription guidelines to counter this tendency.As India seeks to address this pressing health challenge, experts like Dr. Kamini Walia from the Indian Council of Medical Research highlight the need for responsible use of new drugs to avoid a repeat of past mistakes. The ongoing battle requires a multi-faceted approach focusing on hygiene education, vaccination improvements, and comprehensive healthcare reforms.Without immediate action, the ever-growing threat of antibiotic resistance may lead to the era of untreatable infections—a scenario that medical professionals are determined to avoid.
